Last reviewed · How we verify
bile sample analysis
At a glance
| Generic name | bile sample analysis |
|---|---|
| Sponsor | CHU de Reims |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity (NA)
- Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty
- Bile Omics for Diagnosing Indeterminate Biliary Strictures
- "Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures (NA)
- Acquisition of Cardiac Function Parameters in MRI and Echocardiography in Patients with Ethyltoxic Liver Cirrhosis and Transjugular Intrahepatic Portosystemic Shunt (TIPSS) Placement (NA)
- Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer (PHASE2)
- MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers
- Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bile sample analysis CI brief — competitive landscape report
- bile sample analysis updates RSS · CI watch RSS
- CHU de Reims portfolio CI